Category: Journal Club

Written by: Mohsin H. Ali, MD September 2021 Gallardo, Mathias, et al. “Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.” Ophthalmology Retina, vol. 5, no. 7, 2021, pp. 604–624., doi:10.1016/j.oret.2021.05.002.  Machine learning artificial intelligence models have the potential to improve our […]

Written by: Akshay S. Thomas, MD August 2021 Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027-1038.   Treatment options for wet AMD in 2019 included off-label use of bevacizumab or use of an FDA-approved agent, ranibizumab or […]

Written by: Vlad Matei, MD August 2021 Spooner K, Fraser-Bell S, Hong T, et al. Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study. Report 1: ten-year, real-world outcomes. Ophthalmology Retina 2021;5(6):511-518. Neovascular age-related macular degeneration (nAMD) is one of the most common and debilitating diseases encountered by retinal specialists. […]

Written by: Joshua D. Levinson, MD August 2021 Chan CK, Mein CE, Glassman AR, et al. Pneumatic Vitreolysis with C3F8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Ophthalmol. 2021 Treatment options for symptomatic vitreomacular traction (VMT) and macular hole (MH) include observation, pars plana vitrectomy and vitreolysis. […]

Written by: Christopher Aderman, MD July 2021 Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2021 Mar;128(3):417-424. doi: 10.1016/j.ophtha.2020.07.062. Epub 2020 Aug 8. PMID: 32781110. An unfortunate problem we encounter not infrequently in clinic is […]

Written by: Judy Chen, MD July 2021 Koulisis N, Moysidis S, Govindaraju V, et al. Clinical Outcomes and Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis. Retina 2021; 41(6):1242-1250. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medication are the current gold standard of care for patients with neovascular […]

Written by: Maxwell S. Stem, MD June 2021 Kadakia AB, Wong TP, Wykoff CC, Shar AR. Comparison of 25- and 27-gauge Sutureless Cannula-Based Intraocular Lens Scleral Fixation Visual Acuity Outcomes and Complication Rates. Retina. 2021;41(5):940-946. When an intraocular lens (IOL) cannot be safely placed “in the bag,” options for IOL placement include the anterior chamber, […]

Written by: Brian K. Do, MD June 2021 Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wykoff CC, Prenner JL, Boyer DS. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 Mar 18:e210221. doi: 10.1001/jamaophthalmol.2021.0221. Epub […]